GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, announced on September 10, 2026, that it has requested a hearing before the Nasdaq Hearings Panel to appeal a delisting determination received on August 27, 2026, related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The hearing is scheduled for October 13, 2026, and the request has stayed any suspension or delisting action pending the hearing and any extension period granted by the Panel. Consequently, GeoVax's common stock is expected to continue trading on The Nasdaq Capital Market under the symbol "GOVX" at least through that period. At the hearing, the company intends to present its plan to regain and maintain compliance with Nasdaq listing standards.
David Dodd, Chairman and CEO of GeoVax, commented, "We remain committed to maintaining GeoVax's Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel. Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution. We continue to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen our manufacturing and global preparedness capabilities, and engage potential strategic, funding and development partners across our portfolio." He added that the company's focus remains on building long-term value from its vaccine and immuno-oncology programs while addressing near-term corporate and financing priorities, and that progress across its programs, along with growing emphasis on vaccine supply resilience, biodefense preparedness, and expanded global access, provides a strong foundation for continued efforts.
GeoVax's priority program is GEO-MVA, an investigational Modified Vaccinia Ankara (MVA)-based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial addressing the need for expanded orthopoxvirus vaccine supply and biodefense preparedness. In parallel, GeoVax continues to pursue manufacturing and product innovations intended to support broader access and preparedness, while evaluating strategic partnerships and funding opportunities aligned with its development priorities. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. The company also maintains a broader MVA-based vaccine platform and intellectual property portfolio addressing high-consequence infectious diseases and global health preparedness.
The implications of this announcement are significant for GeoVax and its stakeholders. Maintaining its Nasdaq listing is crucial for the company's access to capital and investor confidence, especially as a clinical-stage biotech requiring substantial funding for research and development. The appeal and stay provide a temporary reprieve, but the outcome of the hearing will determine whether GeoVax can continue trading on the exchange. A delisting could reduce liquidity, limit institutional investment, and potentially increase the cost of capital, hindering the company's ability to advance its pipeline. However, GeoVax's reaffirmation of its strategic priorities underscores that its core mission remains intact. The progress of GEO-MVA and Gedeptin, along with a focus on biodefense preparedness and global health, positions the company to address critical public health needs. The growing emphasis on vaccine supply resilience and expanded global access, as noted by Dodd, could attract strategic partners and funding opportunities, even amid the listing challenge. For investors and the broader biotech sector, this update highlights the dual challenges of financial compliance and scientific innovation that clinical-stage companies often face. GeoVax's ability to navigate the Nasdaq process while advancing its programs will be key to its long-term success. More information is available at www.geovax.com.
